Impact of fluorination on proteolytic stability of peptides: A case study with α-chymotrypsin and pepsin

Amino Acids

Volumn 46, Issue 12, 2014, Pages 2733-2744

  Asante, Vivian ^a   Mortier, Jérémie ^a   Wolber, Gerhard ^a   Koksch, Beate ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Aminobutyric acid; Chymotrypsin; Difluoroethylglycine; Pepsin; Trifluoroethylglycine

Indexed keywords

AMINO ACID; ASPARTIC PROTEINASE; CHYMOTRYPSIN A; FLUORINE; GLUCOSE; HEXOSE; HISTONE ACETYLTRANSFERASE; LIGAND; PEPSIN A; PROTEINASE; SERINE PROTEINASE; XYLOSE; ALPHA-CHYMOTRYPSIN; CHYMOTRYPSIN; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; BOVINAE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ESTERIFICATION; FLUORESCENCE ANALYSIS; FLUORINATION; GLYCOSYLATION; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION; ANIMAL; BOVINE; CHEMISTRY; ENZYME STABILITY; MOLECULAR GENETICS; PIG;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; CATTLE; CHYMOTRYPSIN; ENZYME STABILITY; FLUORINE; MOLECULAR SEQUENCE DATA; PEPSIN A; PEPTIDES; PROTEOLYSIS; SWINE;

EID: 84919881413     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1819-7     Document Type: Article

References (83)

1. Aguilar MI (2004) HPLC of peptides and proteins: methods and Protocols. Humana Press, Totowa
2. Antal J, Pál G, Asbóth B, Buzás Z, Patthy A, Gráf L (2001) Specificity assay of serine proteinases by reverse-phase high-performance liquid chromatography analysis of competing oligopeptide substrate library. Anal Biochem 288:156-167. doi: 10.1006/abio.2000.4886
3. Antonov VK, Ginodman LM, Kapitannikov YV, Barshevskaya TN, Gurova AG, Rumsh LD (1978) Mechanism of pepsin catalysis: general base catalysis by the active site carboxylate ion. FEBS Lett 88:87-90
4. Antonov VK, Ginodman LM, Rumsh LD, Kapitannikov YV, Barshevskaja TN, Yavashev LP, Gurova AG, Volkova LI (1981) Studies on mechanism of action of proteolytic enzymes using heavy oxygen exchange. Eur J Biochem 117:195-200
5. Asante V, Mortier J, Schlüter H, Koksch B (2013) Impact of fluorination on proteolytic stability of peptides in human blood plasma. Bioorg Med Chem 21:3542-3546. doi: 10.1016/j.bmc.2013.03.051
6. Baker PJ, Montclare JK (2011) Enhanced refoldability and thermoactivity of fluorinated phosphotriesterase. ChemBioChem 12:1845-18481. doi: 10.1002/cbic.201100221
7. Berman HL, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucl Acids Res 28:235-242
8. Blow DM, Birktoft JJ, Hartley BS (1969) Role of a buried acid group in the mechanism of action of chymotrypsin. Nature 221:337-340
9. Böhm HJ, Banner D, Bendels S, Kansy M (2004) Fluorine in medicinal chemistry. ChemBioChem 5:637-643
10. Brady K, Abeles RH (1990) Inhibition of chymotrypsin by peptidyltrifluoromethyl: determinants of slow-binding kinetics. Biochemistry 29:7608-7617
11. Buer BC, Marsh ENG (2012) Fluorine: a new element in protein design. Prot Sci 21:453-462
12. Chen L, Erickson JW, Rydel TJ, Park CH, Neidhart D, Luly J, Abad-Zapatero C (1992) Structure of a pepsin/renin inhibitor complex reveals a novel crystal packing induced by minor chemical alterations in the inhibitor. Acta Crystallogr B 48(4):476-488
13. Cornish-Bowden AJ, Knowles JR (1969) The pH-dependence of pepsin-catalysed reactions. Biochem J 113:353-362
14. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264
15. Czapinska H, Otlewski J (1999) Structural and energetic determinants of the S1-site specificity in serine proteases. Eur J Biochem 260:571-595
16. Dasgupta P, Singh A, Mukherjee R (2002) N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol Pharm Bull 25:29-36
17. Davies DR (1990) The structure and function of the aspartic proteinases. Annu Rev Biophys Chem 19:189-215
18. Derewenda ZS, Derewenda U, Kobos PM (1994) (His) Cε-H...O = C < hydrogen bond in the active sites of serine. J Mol Biol 241:83-93
19. Dougherty DA (2000) Unnatural amino acids as probes of protein structure and function. Curr Opin Chem Biol 4:645-652
20. Dunn BM (2002) Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem Rev 102:4431-4458
21. Dunn BM, Hung S (2000) The two sides of enzyme-substrate specificity: lessons from the aspartic proteinases. Biochim Biophys Acta 1477:231-240
22. Dunn BM, Jimenez M, Parten BF, Valler MJ, Rolph CE, Kay J (1986) A systematic series of synthetic chromophoric substrates for aspartic proteinases. Biochem J 237:899-906
23. Dunn BM, Valler MJ, Rolph CE, Foundling SI, Jimenez M, Kay J (1987) The pH dependence of the hydrolysis of chromogenic substrates of the type, Lys-Pro-Xaa-Yaa-Phe-(NO2) Phe-Arg-Leu, by selected aspartic proteinases: evidence for specific interactions in subsites S3 and S2. Biochim Biophys Acta 913:122-130
24. Erickson JA, McLoughlin JI (1995) Hydrogen bond donor properties of the difluoromethyl group. J Org Chem 60:1626-1631. doi: 10.1021/jo00111a021
25. Ferrie JJ, Gruskos JJ, Goldwaser AL, Decker ME, Guarracino DA (2013) A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones. Bioorg Med Chem Lett 23:989-995
26. Filler R, Saha R (2009) Fluorine in medicinal chemistry: a century of progress and a 60-years retrospective of selected highlights. Future Med Chem 1:777-791
27. Frackenpohl J, Arvidsson PI, Schreiber JV, Seebach D (2001) The outstanding biological stability of β- and γ-peptides toward proteolytic enzymes: an in vitro investigation with fifteen peptidases. ChemBioChem 2:445-455
28. Fruton JS (1970) The specificity and mechanism of pepsin action. Adv Enzymol Relat Areas Mol Biol 33:401-443
29. Fujinaga M, Chernaia MM, Tarasova NI, Mosimann SC, James MNG (1995) Crystal-structure of human pepsin and its complex with pepstatin. Protein Sci 4:960-972
30. Fujinaga M, Cherney MM, Tarasova NI, Bartlett PA, Hanson JE, James MNG (2000) Structural study of the complex between human pepsin and a phosphorus-containing peptidic - transition-state analog. Acta Crystallogr Sect D56:272-279. doi:
31. Geurink PP, Liu N, Spaans MP, Downey SL, van den Nieuwendijk AMCH, van der Marel GA, Kisselev AF, Florea BI, Overkleeft HS (2010) Incorporation of fluorinated phenylalanine generates highly specific inhibitor of proteasome's chymotrypsin-like sites. J Med Chem 53:2319-2323
32. Giannis A, Kolter T (1993) Peptidomimetics for receptor ligands-discovery, development and medicinal perspectives. Angew Chem Int Ed Engl 32:1244-1267
33. Gottler LM, Lee HY, Shelburne CE, Ramamoorthy A, Marsh ENG (2008) Modulating the biological activity of an antimicrobial peptide using fluorous amino acids. ChemBioChem 9:370-373
34. Hedstrom L (2002) Serine protease mechanism and specificity. Chem Rev 102:4501-4523
35. Hruby VJ (2002) Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov 1:847-858
36. Hua J, Huang K-L (2010) A reversed phase HPLC method for the analysis of nucleotides to determine 5′-PDE enzyme activity. Bull Chem Soc Ethiop 24:167-174
37. Hummel G, Reineke U, Reimer U (2006) Translating peptides into small molecules. Mol BioSyst 2:499-508
38. Isanbor C, O'Hagan D (2006) Fluorine in medicinal chemistry: a review of anticancer agent. J Fluorine Chem 127:303-319
39. Jäckel C, Koksch B (2005) Fluorine in peptide design and protein engineering. Eur J Org Chem 21:4482-4503
40. Jäckel C, Seufert W, Thust S, Koksch B (2004) Evaluation of the molecular interactions of fluorinated amino acids with native polypeptides. ChemBioChem 5:717-720
41. Jäckel C, Salwiczek M, Koksch B (2006) Fluorine in a native protein environment - how space filling and polarity of fluorinated alkyl groups affect protein folding. Angew Chem Int Ed 45:4198-4203
42. Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 245:43-53. doi: 10.1016/S0022-2836(95)80037-9
43. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748. doi: 10.1006/jmbi.1996.0897
44. Kageyama T (2002) Pepsinogens, progastricsins, and prochymosins: structure, function, evolution, and development. Cell Mol Life Sci 59:288-306
45. Keil B (1992) Specificity of proteolysis. Springer, Berlin 335
46. Koksch B, Sewald N, Burger K, Jakubke H-D (1996a) Peptide modification by incorporation of α-trifluoromethyl substituted amino acids. Amino Acids 11:425-434
47. Koksch B, Sewald N, Jakubke H-D, Burger K (1996b) Synthesis and incorporation of α-trifluoromethyl-substituted amino acids into peptides. In: Ojima I, McCarthy JR, Welch JT (eds) Biomedical frontiers of fluorine chemistry, ACS Symposium Series, vol 639. American Chemical Society, Washington DC, pp 42-58
48. Koksch B, Sewald N, Hofmann H-J, Burger K, Jakubke H-D (1997) Proteolytically stable peptides by incorporation of alpha-Tfm amino acids. J Peptide Sci 3:157-167
49. Lee H, Jang IH, Ryu SH, Park TG (2003) N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm Res 20:818-825
50. Łęgowska A, Dębowski D, Lesner A, Wysocka M, Rolka K (2009) Introduction of non-natural amino acid residues into the substrate-specific P1 position of trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors. Bioorg Med Chem 17:3302-3307
51. March TL, Johnston MR, Duggan PJ, Gardiner J (2012) Synthesis, structure, and biological applications of α-fluorinated β-amino acids and derivatives. Chem Biodiversity 9:2410-2441. doi: 10.1002/cbdv.201200307
52. McGregor DP (2008) Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 8:616-619
53. Meng H, Kumar K (2007) Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J Am Chem Soc 129:15615-15622
54. Meng H, Krishnaji ST, Beinborn M, Kumar K (2008) Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1. J Med Chem 51:7303-7307. doi: 10.1021/jm8008579
55. Muller K, Faeh C, Diederich F (2007) Fluorine in pharmaceuticals: looking beyond intuition. Science 317:1881-1886
56. Northrop JH (1930) Crystalline pepsin. I. Isolation and tests of purity. J Gen Physiol 13:739-766
57. Polgár L (2005) The catalytic triad of serine peptidases. Cell Mol Life Sci 62:2161-2172. doi: 10.1007/s00018-005-5160-x
58. Powers JC, Harley AD, Myers DV (1977) Subsite specificity of porcine pepsin. Adv Exp Med Biol 95:141-157
59. Saeki K, Ozaki K, Kobayashi T, Ito S (2007) Enzymatic properties, genes, and crystal structures. J Biosci Bioeng 103:501-508
60. Saffran M, Kumar G, Savariar C, Burnham J, Williams F, Neckers D (1986) A new approach to the oral administration of insulin and other peptide drugs. Science 233:1081-1084
61. Salwiczek M, Samsonov S, Vagt T, Baldauf C, Nyakatura E, Fleige E, Numata J, Cölfen H, Pisabarro MT, Koksch B (2009a) Position dependent effects of fluorinated amino acids on hydrophobic core formation of a coiled coil heterodimer. Chem Eur J 15:7628-7636
62. Salwiczek M, Vagt T, Koksch B (2009b) Artificial model systems designed to investigate fluorinated amino acids in native protein environments. In: Ojima I (ed) Fluorine in bioorganic and medicinal chemistry. Blackwell Publishers, pp 391-409
63. Salwiczek M, Nyakatura EK, Gerling UIM, Ye S, Koksch B (2012) Fluorinated amino acids: compatibility with native protein structures and effects on protein-protein interactions. Chem Soc Rev 41:2135-2171. doi: 10.1039/C1CS15241F
64. Samsonov SA, Salwiczek M, Anders G, Koksch B, Pisabarro MT (2009) Fluorine in protein environments: a QM and MD study. J Phys Chem B 113:16400-16408
65. Sani M, Sinisi R, Viani F (2006) Peptidyl fluoro-ketones as proteolytic enzyme inhibitors. Curr Top in Med Chem 6:1545-1566
66. Sato AK, Viswanathan M, Kent RB, Wood CR (2006) Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17:638-642
67. Schechter I, Berger A (1967) On the size of the active site in proteases. Biochem Biophys Res Com 27:157-162
68. Schellenberger V, Jakubke HD (1986) A spectrophotometric assay for the characterization of the S' subsite specificity of alpha-chymotrypsin. Biochim Biophys Acta 869:54-60
69. Schellenberger V, Turck CW, Rutter WJ (1994) Role of the S' subsites in serine protease catalysis-active-site mapping of rat chymotrypsin, rat trypsin, alpha-lytic protease, and cercarial protease from Schistosoma-Mansoni. Biochem 33:4251-4257
70. Seidel T, Ibis G, Bendix F, Wolber G (2010) Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Tecnol 7:221-228. doi: 10.1016/j.ddtec.2010.11.004
71. Shaji J, Patole V (2008) Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci 70:269-277
72. Shrimpton CN, Abbenante G, Lew RA, Smith AI (2000) Development and characterization of novel potent and stable inhibitors of endopeptidase EC 3.4.24.15. Biochem J 345:351-356
73. Smits R, Koksch B (2006) How C-alpha-fluoroalkyl amino acids and peptides interact with enzymes: studies concerning the influence on proteolytic stability, enzymatic resolution and peptide coupling. Curr Top Med Chem 16:1483-1498
74. Suguna K, Padlan EA, Smith CW, Carlson WD, Davies DR (1987) Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc Natl Acad Sci USA 84:7009-7013
75. Tsukada H, Blow DM (1985) Structure of α-chymotrypsin refined at 1.6 Å resolution. J Mol Biol 184:703-711
76. Vincent HL, Satish DK, George MG, Werner R (1991) Oral route of protein and peptide drug delivery. In: Vincent HL (ed) Peptide and protein drug delivery. Marcel Dekker, New York, pp 691-738
77. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market. Drug Discov Today 15:40-56
78. Voloshchuk N, Zhu AY, Snydacker D, Montclare JK (2009) Positional effects of monofluorinated phenylalanines on histone acetyltransferase stability and activity. Bioorg Med Chem Lett 19:5449-5451
79. Werle M, Bernkop-Schnürch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367. doi: 10.1007/s00726-005-0289-3
80. Wolber G, Langer T (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45:160-169. doi: 10.1021/ci049885e
81. Wolber G, Dornhofer AA, Langer T (2006) Efficient overlay of small molecules using 3-D pharmacophores. J Comput-Aid Mol Des 20:773-788. doi: 10.1007/s10822-006-9078-7
82. Jones G, Willett P, Glen RC http://www.ccdc.cam.ac.uk/products/life-sciences/gold/
83. Zhou P, Tian F, Lv F, Shang Z (2009) Geometric characteristics of hydrogen bonds involving sulfur atoms in proteins. Proteins 76:151-163. doi: 10.1002/prot.22327